Scientists have progressed from merely provoking an anti-cancer immune response to designing it ...

Induces potent and long-lasting immune responses to defined antigens or whole pathogens (particles), mainly through the ...

Chimeric antigen receptor-T (CAR-T) cell therapy, initially successful in hematologic malignancies, presents a promising avenue for treating solid tumors, including CRC. This review explores the ...

Pathogen-fighting immune cells called tissue-resident memory CD8 T cells (TRM cells) go through a surprising transformation -- and relocation -- as they fight infections in the small intestine.

CD19-directed chimeric antigen receptor (CAR) T-cell therapy, originally developed for haematological malignancies, has recently emerged as a promising therapy for patients with autoimmune diseases.

Kathryn Senior reports. Chimeric antigen receptor (CAR) T-cell therapies have proved effective in several haematological cancers including B-cell acute lymphoblastic leukaemia, diffuse large B-cell ...

Communication between MKs and other immune cells is a key aspect of their immune function. MKs secrete cytokines that influence B cell ... pathogen recognition, phagocytosis, and antigen presentation.

A group of immune proteins called the inflammasome can help prevent blood stem cells from becoming malignant by removing certain receptors from ... a mouse model of B-cell lymphoma called Eµ ...

Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.